Consun Pharmaceutical Group Limited (HKG:1681)

Market Cap	14.39B
Revenue (ttm)	3.58B
Net Income (ttm)	1.11B
Shares Out	841.04M
EPS (ttm)	1.29
PE Ratio	13.26
Forward PE	10.99
Dividend	0.66 (3.86%)
Ex-Dividend Date	Sep 4, 2025

Volume	933,400
Average Volume	1,277,463
Open	17.30
Previous Close	17.11
Day's Range	16.66 - 17.30
52-Week Range	7.55 - 17.68
Beta	0.56
RSI	67.82
Earnings Date	Mar 22, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 3,164
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2024, HKG:1681's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY